Sagimet Biosciences Doses First Patient in FASCINATE-2 Phase 2b Trial in NASH Patients with Moderate to Advanced Fibrosis

Sunday, August 15, 2021 1 min read

Key Takeaway: Sagimet Biosciences Doses First Patient in FASCINATE-2 Phase 2b Trial in NASH Patients with Moderate to Advanced Fibrosis

Full Press Release Details

Sagimet Biosciences Doses First Patient in FASCINATE-2 Phase 2b Trial in NASH Patients with Moderate to Advanced Fibrosis.